2%) were diagnosed with NAFLD check details (225 females, or 61.3%), with the average age of 68.7 years. 2) Odds ratios (95% confidence interval (CI)) of factors independently associated with prevalence of NAFLD were 1.27 (1.21-1.33) for BMI per+1kg/m2, 1.7 (1.1 8-2.46) for diabetes, 1.78 (1.40-2.25) for ALT per +10 U/L, and 1.5 (1.08-2.09) for radiation dose at 1 Gy. Those estimates changed little when further adjustment was made for total adiponectin, and the odds ratio (95% CI) for ln (total adiponectin) per +1 unit was 0.23 (0.16-0.33).

3) Among the NAFLD cases, hyaluronic acid levels showed significant positive association with female, age, BMI, past smoking, and diabetes, and type IV collagen levels showed significant positive association with age, BMI, past and current smoking, diabetes, and levels of total adiponectin. Conclusions: Increased prevalence of NAFLD was associated independently with obesity, diabetes, elevated ALT levels, declined levels of total adiponectin, and radiation dose. Severity of liver fibrosis in NAFLD was also associated independently with aging, obesity, smoking habit, diabetes, and elevated levels of total adiponectin. These results suggest that factors such as aging, obesity, smoking habit, diabetes, and change of adiponectin level may be useful as indicators associated with progression of NAFLD. Disclosures: Kazuaki Chayama

– Consulting: Abbvie; Grant/Research Support: Dainippon Epigenetics inhibitor Sumitomo, Chugai, Mitsubishi Tanabe, DAIICHI SANKYO, Toray, BMS, MSD; Speaking and Teaching: Chugai, Mitsubishi Tanabe, DAIICHI SANKYO, KYORIN, Nihon Medi-Physics, BMS, Dainippon Sumitomo, MSD, ASKA, Astellas, AstraZeneca, Eisai, Olympus, GlaxoSmithKline, ZERIA, Bayer, Minophagen, JANSSEN, JIMRO, TSUMURA, Otsuka, Taiho, Nippon Kayaku, Nippon Shinyaku, Takeda, AJINOMOTO, Meiji Seika, Toray The following people have nothing to disclose: Waka Ohishi, Keiko Ueda, Yoshimi Tatsukawa,

Eiji Nakashima, Michiko Yamada, Ikuno Takahashi, Masataka Tsuge Background: A reliable and inexpensive noninvasive marker of hepatic fibrosis is required in patients with nonalcoholic fatty liver disease (NAFLD). AST/ALT ration (AAR) and platelet (PLT) count have been medchemexpress expected to detect or exclude advanced fibrosis in chronic liver diseases. The aim is to examine whether the combination of AAR and PLT is useful to detect or exclude advanced stages of NAFLD. Methods: A total of 259 patients (male: female= 134: 125, age 54.0±15.9 yr) with biopsy-proven NAFLD were involved in the present study. Advanced fibrosis was defined as stage 3 or 4 fibrosis according to Brunt’s criteria. The areas under the receiver operating characteristic curves (AUROC) were compared.The Youden index was used to identify the optimal cutoff points. Results: A total of 139 subjects had steatohepatitis, of whom 64 subjects (11 %) had advanced fibrosis.